-0.63%
Today
Loading 1D prices…
Company profile
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Philadelphia, PA, United States
Employees
15
Fiscal year end
1231
CIK
1842952
Session & valuation
Latest annual period
Deterministic peer set
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| KYNBKyntra Bio Inc. Common Stock | $32.3M | $6.4M | +2848.63% | $45.37 | -0.06% | Buy |
| RMTIRockwell Medical Inc. Common Stock | $32.1M | $69.3M | -7.67% | -$0.15 | +1.61% | Buy |
| NXTCNextCure Inc. Common Stock | $32M | $0.00 | — | -$19.65 | -4.24% | Buy |
| MIRAMIRA Pharmaceuticals Inc. Common Stock | $32.5M | $0.00 | — | -$1.35 | -1.90% | Buy |
| CPHIChina Pharma Holdings Inc. Common Stock | $32.7M | $4.1M | -76.91% | -$0.74 | 0.00% | Unrated |